Synthis Therapeutics is a preclinical stage biotech company, pioneering a novel antibody drug conjugate (ADC) to treat fibrotic and inflammatory diseases, including IPF and myelofibrosis. Elevated TGF-b drives organ scarring and fibrosis but systemic TGF-b therapies, which blocks TGF-b everywhere, causes significant host toxicity. At Synthis, we have solved this problem by developing SYN303, an ADC that cell-selectively and safely blocks TGF-b in disease areas to improve the therapeutic window. SYN303 blocks both organ fibrosis and inflammation in vivo. We have developed the only ADC in the TGF-b space, with both a differentiated modality and mechanism of action. With 9 issued patents, we are currently raising a $25M Series A for first in human clinical trials in myelofibrosis patients. At Synthis, we have solved the problem of systemic TGF-b inhibitor toxicity and have developed novel therapeutic options for cancer and fibrosis patients.